Company / Capital Returned to Shareholders
Sarepta Therapeutics Capital Returned to Shareholders History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$25.0M
FY2025
5-year range
$0 / $25.0M
FY2023-FY2025
Trend
-
vs FY2024
Sector context
#35 of 52
Health Care
What the data says
At $25M, Sarepta Therapeutics's capital returned to shareholders ranks #35 of 52 in the Health Care sector. Improved from $0 to $25M over the past 2 years.
Based on SEC 10-K filings.
$25M in FY2025.
Improved from $0 to $25M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#35 of 52 in Health CareTop 67% of 52This company $25.0M Sector average $1.3B
▼
-98.1% below sector average
Key checks
Key Insights
- Ranks #35 out of 52 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.0M | - |
| FY2024 | $0 | - |
| FY2023 | $0 | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026